Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Paul Prescott Just Put Nasus Pharma Ltd. (NYSE: NSRX) On This Morning's Watchlist—Wednesday, March 25, 2026
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Full Coverage On (NSRX) is Starting Right Now
Get (NSRX) On Your Screen While It's Still Early…
March 25, 2026
Breaking News | (NSRX) Makes Approx. 25% Overnight Move on Early Headline Dear Reader, Breaking news just crossed the wire this morning—and it's already putting (NSRX) in focus early. Shares of (NSRX) have already tapped $2.96 today, marking an approximate 25% move from yesterday's $2.35 range, as fresh updates begin to circulate. The company just announced it is advancing its lead intranasal epinephrine program, NS002, toward a pivotal study following positive Phase 2 results that showed faster early absorption compared to EpiPen®. Alongside that, management highlighted continued pipeline expansion and stated it is funded through the planned pivotal study and a potential NDA filing. With multiple clinical milestones lining up into 2026, this update is helping explain why (NSRX) is back on the radar this morning. If you missed my earlier email coverage, keep reading to quickly get up to speed on why we're so excited to be highlighting (NSRX) today. ===== At Street Ideas, we pay close attention when a new approach begins to reshape how critical care is delivered. In emergency situations, speed, simplicity, and ease of use can make a meaningful difference—and that's exactly where innovation is starting to take hold. The shift toward needle-free treatment methods is gaining traction across the medical community as more attention turns to faster, more accessible delivery systems. One company positioning itself within that shift is Nasus Pharma Ltd. (NYSE: NSRX), with its proprietary intranasal powder technology designed for acute allergic emergencies. And that's exactly why (NSRX) just hit the Street Ideas radar and is topping our watchlist this morning—Wednesday, March 25, 2026. But keep in mind, (NSRX) has less than 4M shares listed as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift. And as the story around (NSRX) continues to build, several analysts have started to take notice in a big way. Analyst Targets Suggest 700% to Over 800% Upside Potential for (NSRX)
One firm, Laidlaw, has issued a Bullish rating with a 12-month target of $22, which suggests over 800% upside potential from its recent $2.35 range. Furthermore, Jason Butler at Citizens JMP initiated coverage with a $19 target, which suggests over 700% upside potential. This target represents even higher growth potential, driven by their belief that NS002 is a fast-acting treatment with a lower risk in clinical development compared to many peers. The analysts highlight that the maturing acceptance of non-injectable treatments creates a tailwind that (NSRX) is perfectly positioned to capture. And once you take a closer look at what (NSRX) is building, it becomes even easier to see why this story is starting to stand out. The combination of speed, innovation, and a clear focus on real-world emergency use is what makes (NSRX) a name worth watching right now. Redefining Emergency Care
Based in Israel, Nasus Pharma Ltd. (NYSE: NSRX) is a clinical-stage pharmaceutical firm dedicated to developing intranasal powder products for acute medical conditions. Their lead candidate, NS002, is a powder-based intranasal Epinephrine formulation designed to replace traditional autoinjectors. By leveraging the rich vascular network of the nasal cavity, their Proprietary Powder-Based Intranasal (PBI) technology aims to provide rapid, reliable, and user-friendly delivery. Unlike liquid nasal sprays, which can suffer from runoff or inconsistent absorption, (NSRX) utilizes uniform spherical powder particles. This allows for broad dispersion and potentially faster, higher absorption levels. This distinction is critical in emergency settings where every second counts. The company's recent operational milestones, including a successful $15M private placement in February 2026, suggest a strengthened balance sheet to support their advancing clinical programs. The Shift to Needle-Free Solutions
The medical landscape for emergency allergy treatment has remained largely stagnant for decades, dominated by the traditional autoinjector. However, Nasus Pharma Ltd. (NYSE: NSRX) is challenging this status quo. The core of the company's value proposition lies in the PBI technology, which addresses the fundamental limitations of current rescue medications. Intranasal administration is uniquely suited for situations requiring rapid dr-ug delivery while removing the psychological and physical barriers associated with needles. Clinical Superiority and Data Milestones
The primary driver for Nasus Pharma Ltd. (NYSE: NSRX) is the robust data emerging from its Phase 2 clinical studies. In January 2026, interim results revealed that NS002 achieved the critical 100 pg/ml plasma threshold in 91% of participants within just 5 minutes. For comparison, the industry-standard EpiPen® only reached this mark in 67% of participants in the same timeframe. This speed of absorption is a potential game-changer. In cases of anaphylaxis, the Cmax and Tmax—the peak concentration and the time it takes to reach it—are the most vital metrics for survival and recovery. The Phase 2 study was specifically designed to compare these pharmacokinetic markers against the EpiPen, and so far, the results have been exceptionally encouraging. (NSRX) recently reported positive top-line results from its Phase 2 clinical study of NS002, highlighting faster and more efficient epinephrine delivery compared to the traditional EpiPen®. The study showed NS002 reached the critical 100 pg/mL threshold in a median time of 1.69 minutes versus 3.42 minutes for EpiPen®, with a higher percentage of participants achieving therapeutic levels within the first five minutes. NS002 also demonstrated increased dr-ug exposure during the key early treatment window, along with comparable peak concentration levels and a favorable safety profile with no serious adverse events reported. These results support the company's plan to initiate a pivotal study in the fourth quarter of 2026 as it advances the program toward potential regulatory milestones. Market Potential and Competitive Positioning
The anaphylaxis treatment market is substantial and has long been dominated by a small number of injectable products. At the same time, interest in non-injectable alternatives continues to grow. (NSRX) believes NS002 stands out because its powder formulation is designed to avoid the stability and delivery challenges often associated with liquid-based nasal sprays. If the Phase III study begins as planned in mid-2026, the company could report topline data by year-end 2026, supporting its broader regulatory timeline and a possible approval path by 2028. A Strategic Path to Commercialization
Rather than attempting to build a massive global sales force from scratch, Nasus Pharma Ltd. (NYSE: NSRX) has indicated a strategy focused on out-licensing NS002 for commercialization. This is a common and often successful move for clinical-stage firms, as it allows them to leverage the infrastructure of a major pharmaceutical partner while retaining high-margin royalty streams. The company's leadership has been significantly bolstered to navigate this transition. The appointment of Eyal Rubin as CFO in late 2025 brought in an executive with a proven track record in financial strategy and corporate growth. This leadership, combined with the recent $15M funding, ensures the company has the resources to execute its clinical roadmap over the next 18 to 24 months. 
Unpacking the Technology: The PBI Advantage
What sets Nasus Pharma Ltd. (NYSE: NSRX) apart is the science behind the delivery. The Proprietary Powder-Based Intranasal (PBI) technology uses specialized, uniform particles. In liquid sprays, droplets can often cluster or be swallowed, leading to inconsistent dosing. Powder particles, however, are designed to coat the nasal mucosa evenly. This broad dispersion is what allows for the rapid absorption levels that were seen in the Phase 2 interim results. Furthermore, powder formulations are often more stable across varying temperatures compared to liquids. For a product like Epinephrine, which patients must carry with them at all times—often in pockets or bags—this thermal stability is a significant practical advantage for the end-user. A Multi-Program Pipeline Built on Intranasal Powder Technology
Nasus Pharma's pipeline centers on its intranasal powder delivery platform and includes several candidates across different stages of development. The company's lead program, NS002, is an intranasal epinephrine candidate for anaphylaxis that has reported Phase 2 repeat-dose pharmacokinetic interim results, with a pivotal study expected to begin in Q4 2026. Additional pipeline programs include NS003, an intranasal ondansetron candidate for nausea and vomiting, currently in preclinical development with a first-in-human study expected in the second half of 2026, as well as NS004 targeting metabolic conditions and NS005 focused on cardiovascular indications, both also in the preclinical stage. The company also lists NS001, an intranasal naloxone candidate for opioid overdose, which has completed a pivotal Phase 3 study (n=42) and is currently available for partnering. Overall, the pipeline reflects a strategy focused on applying the company's intranasal powder technology across multiple acute medical conditions. The 2025/2026 Vision: Execution on All Fronts
In the CEO's 2025 Letter to Shareholders, the company outlined a clear vision for aggressive clinical advancement. The initiation of the Phase 2 study in November 2025 was a milestone that set the stage for the current momentum. The company is not just focusing on Epinephrine; their platform technology has the potential to be applied to a variety of acute medical conditions where "needle-free" and "fast-acting" are the primary requirements. 7 Reasons Why (NSRX) is Topping Our Watchlist This Morning
—Wednesday, March 25, 2026.…
1. Low Float: With fewer than 4M shares publicly available, (NSRX) has a limited float that can amplify movement as interest increases. 2. Analyst Targets: Coverage from multiple firms has placed (NSRX) in focus with targets suggesting roughly 700% to over 800% upside potential from recent levels. 3. Needle-Free Trend: A growing shift toward non-injectable emergency care is helping bring attention to what (NSRX) is developing. 4. Strong Data: Phase 2 results showed (NSRX) reached key epinephrine levels faster than EpiPen® in a majority of participants. 5. Faster Delivery: Top-line data revealed (NSRX) achieved the critical threshold in 1.69 minutes versus 3.42 minutes for EpiPen®. 6. Pipeline Depth: Beyond its lead program, (NSRX) is advancing multiple intranasal candidates across several acute conditions. 7. Upcoming Milestones: Plans for a pivotal study in Q4 2026 position (NSRX) with a clear clinical roadmap Get (NSRX) On Your Screen While It's Still Early…
Taken together, these seven factors help explain why (NSRX) is starting to attract attention. A small public float, encouraging Phase 2 data, and analyst targets pointing to significantly higher levels have placed the company on many watchlists. At the same time, its proprietary intranasal powder platform and focus on needle-free emergency treatment position (NSRX) within a growing shift toward more convenient delivery methods. Add in recent funding and the possibility of a Phase III study beginning in mid-2026, and the story surrounding (NSRX) becomes one that many readers may want to understand more closely. We have all eyes on (NSRX) this morning—Wednesday, March 25, 2026. Take a look at (NSRX) while it's still early. Also, keep an eye out for my next update—it could be hitting very shortly. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter | 
Tidak ada komentar:
Posting Komentar